

# Understanding the Medicare Drug Price Negotiation Program (MDPNP)

In August 2022, the Inflation Reduction Act (P.L. 117-169) was signed into law. For the first time, the law provides Medicare the ability to directly negotiate the prices of certain high expenditure, single source Medicare Part B and Part D drugs without generic or biosimilar competition through the Medicare Drug Price Negotiation Program (MDPNP). These negotiated prices, referred to as Maximum Fair Prices (MFPs), are based on negotiations and agreements reached between the Centers for Medicare & Medicaid Services (CMS) and participating drug manufacturers.

In August 2023, CMS selected 10 drugs covered under Medicare Part D for the first cycle of negotiations with MFPs going into effect in 2026. In January 2025, CMS announced the selection of 15 additional drugs covered under Medicare Part D for the second cycle of negotiations with MFPs expected to go into effect in 2027.

## First round of Medicare Part D drugs selected for negotiated pricing effective January 1, 2026

- Eliquis®
- Enbrel®
- Entresto®
- Farxiga®
- Fiasp®; Fiasp® FlexTouch; Fiasp® PenFill; NovoLog®; NovoLog® Flexpen; NovoLog® PenFill
- Imbruvica®
- Januvia®
- Jardiance®
- Stelara®
- Xarelto®

### CMS fact sheet

To view 2026 MFP drug pricing or learn more about CMS' negotiation process for the drugs listed above, scan or click the QR code.



## Second round of Medicare Part D drugs selected for negotiated pricing effective January 1, 2027

- Austedo®; Austedo XR®
- Breo Ellipta
- Calquence®
- Ibrance®
- Janumet®; Janumet® XR
- Linzess®
- Ofev®
- Otezla®
- Ozempic®; Rybelsus®; Wegovy®
- Pomalyst®
- Tradjenta®
- Trelegy Ellipta
- Vraylar®
- Xifaxan®

### CMS fact sheet

To view 2027 MFP drug pricing or learn more about CMS' negotiation process for the drugs listed above, scan or click the QR code.



# Medicare Drug Price Negotiation Program: Key milestones through 2027

**2023**

**August 29**

CMS announced 10 Medicare Part D drugs selected for first round of negotiations

**2024**

**August 1**

First negotiation period between CMS and participating drug manufacturers ends

**August 15**

CMS published maximum fair prices for first round of selected drugs effective 2026

**2025**

**January 17**

CMS announced 15 more Medicare Part D drugs selected for second round of negotiations

**Spring**

CMS intends to release draft guidance for the third cycle of negotiations with MFP effective in 2028, including new policies on renegotiation and Part B drugs

**Fall/Winter**

CMS intends to release final guidance on third cycle of negotiations with MFP effective in 2028, including new policies on renegotiation and Part B drugs

**November 1**

Second negotiation period between CMS and participating drug manufacturers ends

**November 30**

Deadline for CMS to publish the maximum fair prices for second round of selected drugs effective 2027

**2026**

**January 1**

Maximum fair prices are effective for the first round of drugs selected in 2023

**March 1**

Deadline for CMS to publish explanations of agreed-upon MFPs for the second rounds of selected drugs

**2027**

**January 1**

Maximum fair prices are effective for the second round of drugs selected in 2025